We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More

In less than five hours from now, President and CEO of Actinium Pharmaceuticals Dr. Kaushik J. Dave will be presenting a corporate update at the Biotech Showcase™ 2014 in San Francisco, CA.

The presentation starts at 4:30pm Pacific at the Wyndham Hotel. For those unable to join in person, the company has provided the following webcast link: www.media-server.com/m/p/qbc4c7nh.

Actinium Pharmaceuticals is a biopharmaceutical company with a proprietary platform that combines the precision targeting of monoclonal antibodies with the killing power of alpha and beta radioisotopes, the former being the most potent cancer killing agents in existence. Leveraging this platform and its ties with leading cancer institutions, the company is focused on developing drugs for underserved cancers with no approved drugs which have multi-billion dollar market potential.

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.